Humacyte Inc.
HUMA evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $157.7M
What it means
What to watch
Prepared research question
What matters most for HUMA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HUMA
Humacyte Inc. is a commercial-stage biotechnology platform company developing universally implantable acellular tissue engineered vessels (ATEVs) for vascular repair and reconstruction, with its first product Symvess approved in the U.S. and ongoing clinical programs in dialysis access, vascular trauma, coronary artery bypass, and congenital heart defects.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$157.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 10 clinical trials for Humacyte Inc..
Humacyte Inc. is a commercial-stage biotechnology platform company developing universally implantable acellular tissue engineered vessels (ATEVs) for vascular repair and reconstruction, with its first product Symvess approved in the U.S. and ongoing clinical programs in dialysis access, vascular trauma, coronary artery bypass, and congenital heart defects.
- Humacyte's lead product Symvess (acellular tissue engineered vessel) is commercially available in the U.S. for vascular replacement or reconstruction in life- or limb-threatening vascular trauma [sec_mda · as of 2026-08-12].
- Phase 3 dialysis access data showed ATEV outperformed standard of care for female patients; the company plans to file a supplemental Biologics License Application based on these results [news · published 2026-08-13].
- The FDA accepted an Investigational New Drug application for Humacyte's new coronary vessel candidate, allowing clinical development to proceed [news · published 2026-08-13].
- As of June 30, 2026, Humacyte had cash and cash equivalents of $79.9 million and reported a net loss of $36.8 million for the six months then ended [sec].
- The company expects to incur substantial operating losses and negative cash flows for the foreseeable future and will need additional funding to support commercialization and development activities [sec_mda · as of 2026-08-12].
What works
- Symvess is a first-in-class acellular tissue engineered vessel already approved and commercialized in the U.S., providing a novel option for vascular trauma repair [sec_mda · as of 2026-08-12].
- Positive Phase 3 results in female dialysis patients and peer-reviewed publication in The Lancet Digital Health support the clinical value of ATEV in high-risk populations [news · published 2026-08-19].
- The FDA's acceptance of an IND for a coronary vessel candidate expands the pipeline into a large cardiovascular market [news · published 2026-08-13].
What to weigh
- Humacyte has a history of operating losses and negative cash flows; as of June 30, 2026, it had only $79.9 million in cash and expects insufficient liquidity to fund operations beyond one year [sec_mda · as of 2026-08-12].
- The company will need additional funding to continue commercialization, clinical trials, and manufacturing scale-up, and such capital may not be available on acceptable terms [sec_mda · as of 2026-08-12].
- Product revenue from Symvess is still nascent ($0.4 million total revenue in the first half of 2026), and the ability to generate sufficient revenue to finance operations is uncertain [sec].
From the filings
Quoted directly from source documents.
Symvess is commercially available in the U.S. for vascular trauma
“commercial-stage biotechnology platform company developing universally implantable”
SEC MD&A · August 19, 2026
Phase 3 dialysis data showed ATEV outperformed standard of care for women
“Humacyte (NasdaqGS:HUMA) reported Phase 3 dialysis access data showing its acellular tissue engineered vessel outperformed standard of care for female patients.”
News · August 13, 2026
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents of $79.9 million and restricted cash of $0.4 million.”
SEC MD&A · August 12, 2026
Company expects to need additional funding
“We will need additional funding in connection with these activities.”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2016-12-20 · Phase 2 start for femoro-popliteal bypass in peripheral arterial disease — Historical start of a Phase 2 trial evaluating ATEV for peripheral arterial disease.
- 2017-09-29 · Phase 3 start for hemodialysis access — Historical start of a Phase 3 trial comparing ATEV to autologous arteriovenous fistula in ESRD patients.
- 2018-09-01 · Phase 2/3 start for vascular trauma — Historical start of a Phase 2/3 trial for ATEV in life- or limb-threatening vascular trauma.
- 2023-09-07 · Phase 3 start for hemodialysis access (additional study) — Historical start of a Phase 3 randomized study comparing ATEV efficacy and safety in dialysis access.
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — As of June 30, 2026, cash of $79.9M is insufficient to fund operations beyond one year [sec_mda · as of 2026-08-12].
- Dependence on additional financing — Adequate capital may not be available on acceptable terms to support commercialization and R&D [sec_mda · as of 2026-08-12].
- Limited product revenue — Total revenue was only $0.4M in H1 2026; revenue generation from Symvess is still early [sec].
- Regulatory and clinical risks — Success of supplemental BLA for dialysis access and other pipeline candidates is uncertain [news · published 2026-08-13].
What to watch
- Supplemental Biologics License Application filing for ATEV in female dialysis patients [news · published 2026-08-13].
- Progress of the coronary vessel candidate IND and early clinical development [news · published 2026-08-13].
- Commercial sales trajectory of Symvess and ability to generate recurring product revenue [sec_mda · as of 2026-08-12].
- Any capital-raising activities or strategic partnerships to extend cash runway [sec_mda · as of 2026-08-12].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Humacyte Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Humacyte Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 3.42 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
4 buys · 2 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
157
Total value held
$35.6M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 12,316,955 | $7.5M |
| vanguard capital management llc | 7,158,162 | $4.3M |
| antipodes partners ltd | 5,723,750 | $3.5M |
| great point partners llc | 3,750,000 | $2.3M |
| geode capital management, llc | 3,658,108 | $2.2M |
| state street corp | 3,043,929 | $1.8M |
| ubs group ag | 2,782,070 | $1.7M |
| woodline partners lp | 2,002,582 | $1.2M |
| aqr capital management llc | 1,924,691 | $1.2M |
| vanguard portfolio management llc | 1,417,825 | $861K |
Showing top 10 of 157 institutional holders of Humacyte Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 20.9%
- Days to cover
- 4.5
- Shares short
- 42,223,438
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HUMA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Humacyte Inc.?
Humacyte Inc. is a commercial-stage biotechnology platform company developing universally implantable acellular tissue engineered vessels (ATEVs) for vascular repair and reconstruction, with its first product Symvess approved in the U.S. and ongoing clinical programs in dialysis access, vascular trauma, coronary artery bypass, and congenital heart defects.
Who is the CEO of Humacyte Inc.?
Dr. Laura E. Niklason M.D., Ph.D. is the chief executive officer of Humacyte Inc. (HUMA).
Where is Humacyte Inc. headquartered?
Humacyte Inc. (HUMA) is headquartered in Durham, NC, United States.
What therapeutic areas does Humacyte Inc. focus on?
Humacyte Inc. develops therapies across Cardiovascular, Metabolic, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.